comparemela.com

Latest Breaking News On - Zanubrutinib - Page 3 : comparemela.com

Revisit the Top 5 OncLive On Air Episodes of 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

United statesNational taiwan university hospitalT ai peiFrance generalUniversity of chicagoSan antonioNew yorkDana farber cancer instituteRegion flamandeInstitut curieFrancois clement bidardPatrick borgenTerence friedlanderLisaa careyArielle medfordConstantine tam

Zanubrutinib Plus Sonrotoclax in Patients With Treatment-Naïve CLL/SLL

Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.

Targeted therapiesB cell malignanciesPlus sonrotoclaxPatients with treatment naChronic lymphocytic leukemiaCll treatmentsChronic lymphocytic leukemia treatmentsBgb 11417 101Bcl2 inhibitor

Broad Superiority of Zanubrutinib Over Bendamustine + Rituximab Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without del(17p)

Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).

Constantines tamEuropean research initiativeBroad superiorityZanubrutinib over bendamustineRituximab across multiple high risk factorsBiomarker subgroup analysisPatients with treatment naive chronic lymphocyticSmall lymphocytic lymphoma withoutClinical practiceSequoia studyChronic lymphocytic leukemiaDeletion 17p17p deletionNext generation sequencing

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

San diegoUnited statesJenniferr brownExtended follow upZanubrutinib versus ibrutinibRefractory chronic lymphocytic leukemiaSmall lymphocytic lymphomaPartnership withAlpine studyChronic lymphocytic leukemiaBtk inhibitorCll treatmentAlpine trialAlpine study dataAlpine study resultsAlpine extended follow up

Zanubrutinib Improves PFS in Treatment-Naive CLL/SLL, Regardless of Complex Karyotypes

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

San raffaele scientific instituteDivision of experimental oncologyStrategic research programB cell neoplasia unitVita salute sanExperimental oncologyPhase 3 sequoia trial nct03336333

vimarsana © 2020. All Rights Reserved.